Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 2/20 | 0.65 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.53 |
| ▸ | HPGD | P15428 | 4/20 | 0.53 |
| ▸ | MEN1 | O00255 | 2/20 | 0.53 |
| ▸ | MAPT | P10636 | 1/20 | 0.53 |
| ▸ | THRB | P10828 | 1/20 | 0.53 |
| ▸ | POLB | P06746 | 1/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.50 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.50 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.50 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.47 |
| ▸ | TSHR | P16473 | 2/20 | 0.47 |
| ▸ | RAB9A | P51151 | 1/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.45 |
| ▸ | P2RX3 | P56373 | 1/20 | 0.43 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.43 |
| ▸ | GABRB2 | P47870 | 1/20 | 0.43 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.42 |
| ▸ | HTT | P42858 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Trifluoroacetic Acid SCHEMBL4392488 | 0.94 | LMNA (0.59) | LMNAKMT2AHPGDMEN1MAPT | |
| SCHEMBL4391074 | 0.93 | LMNA (0.68) | LMNAKMT2AHPGDMEN1MAPT | |
| Iodide SCHEMBL4391070 | 0.92 | LMNA (0.67) | LMNAKMT2AHPGDMEN1MAPT | |
| SCHEMBL5681141 | 0.92 | LMNA (0.54) | LMNAKMT2AHPGDMEN1MAPT | |
| SCHEMBL5430744 | 0.91 | LMNA (0.53) | LMNAKMT2AHPGDMEN1MAPT | |
| SCHEMBL5444342 | 0.91 | LMNA (0.53) | LMNAKMT2AHPGDMEN1MAPT | |
| SCHEMBL4172191 | 0.90 | LMNA (0.67) | LMNAKMT2AHPGDMEN1MAPT | |
| SCHEMBL5427795 | 0.90 | LMNA (0.53) | LMNAKMT2AHPGDMEN1MAPT | |
| SCHEMBL5437230 | 0.89 | SMN1; SMN2 (0.52) | LMNAKMT2AHPGDMEN1MAPT | |
| SCHEMBL4391354 | 0.89 | LMNA (0.71) | LMNAKMT2AHPGDMEN1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7569550-B2 | 14 and 15 membered ring compounds | GLAXO GROUP LIMITED (GB) | 2009-08-04 | — | — | US | disclosed |
| US-20090062218-A1 | MACROLONE COMPOUNDS | GLAXO GROUP LIMITED (GB) | 2009-03-05 | — | — | US | disclosed |
| US-20070293472-A1 | Novel 14 and 15 Membered Ring Compounds | GLAXO GROUP LIMITED (GB) | 2007-12-20 | — | — | US | disclosed |
| US-20070185117-A1 | Novel 14 and 15 membrered ring compounds | GLAXO GROUP LIMITED (GB) | 2007-08-09 | — | — | US | disclosed |
| EP-1628989-B1 | NOVEL 14 AND 15 MEMBERED-RING COMPOUNDS | GLAXO GROUP LTD (GB) | 2006-12-20 | — | — | EP | disclosed |
| EP-1628988-B1 | NOVEL 14 AND 15 MEMBERED-RING COMPOUNDS | GLAXO GROUP LTD (GB) | 2006-10-04 | — | — | EP | disclosed |
| EP-1628988-A1 | NOVEL 14 AND 15 MEMBERED-RING COMPOUNDS | GLAXO GROUP LIMITED (GB) | 2006-03-01 | — | — | EP | disclosed |
| EP-1628989-A1 | NOVEL 14 AND 15 MEMBERED-RING COMPOUNDS | GLAXO GROUP LIMITED (GB) | 2006-03-01 | — | — | EP | disclosed |
| WO-2004101587-A1 | NOVEL 14 AND 15 MEMBERRED-RING COMPOUNDS | GLAXO GROUP LIMITED (GB) | 2004-11-25 | — | — | WO | disclosed |
| WO-2004101586-A1 | NOVEL 14 AND 15 MEMBERED-RING COMPOUNDS | GLAXO GROUP LIMITED (GB) | 2004-11-25 | — | — | WO | disclosed |
| WO-2004101584-A1 | MACROLIDES SUBSTITUTED AT THE 3-POSITION HAVING ANTIMICROBIAL ACTIVITY | GLAXO GROUP LIMITED (GB) | 2004-11-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070185117-A1 | Novel 14 and 15 membrered ring compounds | CYP51A1, LSS, IL17A | LMNA 2615/4885KMT2A 4774/4885HPGD 1267/4885 |
| US-20070293472-A1 | Novel 14 and 15 Membered Ring Compounds | IL17A, CYP51A1, IL15 | LMNA 4168/4885KMT2A 4650/4885HPGD 1054/4885 |
| US-20090062218-A1 | MACROLONE COMPOUNDS | CYP51A1, MRPL21, MYD88 | LMNA 1055/4885KMT2A 3931/4885HPGD 2617/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.